AstraZeneca's decision to cut another 2,200 jobs out of its R&D ops is underscoring a shift from in-house work to a greater reliance on external ties. As AstraZeneca ($AZN) finds itself under severe pressure from falling profits, the pharma giant has decided to go "virtual" on its neuroscience work. And that will speed the industry trend toward outsourcing more discovery and development work to its academic and industry partners. Story